Key Highlights
- Union Health Minister J.P. Nadda officially unveiled an Indian‑produced tetanus‑diphtheria (Td) vaccine at the Central Research Institute (CRI), Kasauli.
- The new Td formulation will replace the older tetanus toxoid (TT) dose in India's Universal Immunisation Programme (UIP) as per WHO and NTAGI recommendations.
- Initial allocation of 5.5 million doses is slated for delivery by April 2026, with capacity to expand in later years.
- India’s UIP now protects nearly 99% of the target population, encompassing 5 crore beneficiaries each year.
- The launch underscores India’s ambition for vaccine self‑sufficiency and its standing as a global manufacturing hub.
Detailed Insights
On a ceremony at CRI Kasauli, Minister Nadda hailed the indigenous Td vaccine as a watershed moment for national health security. The product, manufactured under Good Manufacturing Practices (GMP), has cleared developmental, licensing, and marketing milestones, and is cleared by the Central Drugs Laboratory for commercial distribution. By substituting TT with Td, India aligns with the 2006 WHO directive and the 2017 WHO Position Paper, which advocate broader diphtheria protection alongside tetanus immunity.
The vaccine will be integrated into the routine immunisation schedule for infants, children, adolescents, and pregnant women, thereby widening the protective umbrella across age groups. The UIP, the world’s largest vaccination effort, administers 27 doses from pregnancy through age 16, utilizes the U‑WIN digital tracking system, and provides five antenatal check‑ups—including at least one specialist visit—for expectant mothers.
Key Concepts
- Tetanus‑Diphtheria (Td) vaccine: A combined injectable that confers immunity against tetanus—a nerve‑paralysis disease caused by bacterial toxin—and diphtheria, a respiratory infection that can cause severe airway obstruction.
- Universal Immunisation Programme (UIP): India’s national scheme that delivers free vaccines against eleven diseases to roughly 5 crore individuals annually, making it the largest public‑health immunisation initiative worldwide.
- Good Manufacturing Practices (GMP): A set of guidelines ensuring that pharmaceutical products are consistently produced and controlled to quality standards appropriate for their intended use.